Tag
This international multicenter study shows no significant difference in surgical complications or survival between tangential and segmental portomesenteric venous resections during pancreatoduodenectomy for pancreatic cancer with limited ve
This article explores how acquired resistance to gemcitabine in pancreatic cancer leads to metabolic reprogramming that creates a vulnerability in the mevalonate pathway, offering a promising therapeutic target.
Emerging evidence demonstrates that KRAS mutation analysis in secretin-stimulated duodenal lavage fluid offers a minimally invasive and sensitive approach for early detection of resectable pancreatic ductal adenocarcinoma, outperforming tra
Temporary mesoportal and mesocaval portal vein bypasses are effective surgical strategies in pancreatectomy with portal vein resection, offering comparable perioperative outcomes and facilitating safe resection of advanced pancreatic tumors
An integrated genomic and pharmacologic analysis identifies IMPDH2 as a key vulnerability in KRAS-mutant pancreatic cancer, showing that irreversible guanine nucleotide depletion potentiates KRAS-targeted therapies and offers a novel combin
MTFP1 promotes pancreatic ductal adenocarcinoma liver metastasis by enhancing mitochondrial oxidative phosphorylation via the ROS/PI3K/AKT/c-MYC/SLC1A5 axis, revealing a promising therapeutic target to reverse tumor immune suppression and r
This multicenter study evaluates how the surgical learning phase impacts major complications and oncological quality in robotic left-sided pancreatectomy, demonstrating safe adoption with consistent morbidity and highlighting the need for o
This study employs interpretable anomaly-detection algorithms to identify high-risk phenotypes in resected solid pseudopapillary pancreatic tumors, overcoming limitations of conventional survival models in ultra-rare cancer-specific deaths.
A multicenter study developed a robust exosomal microRNA-based model enabling preoperative detection of occult liver micrometastasis in pancreatic ductal adenocarcinoma, improving risk stratification and guiding treatment sequencing.
CAR T cells targeting the CA19-9 glycan show potent, specific anti-tumor activity in pancreatic and various gastrointestinal cancers, providing new avenues for immunotherapy of hard-to-treat solid tumors.
This study analyzes nationwide data from Japan comparing robotic, laparoscopic, and open distal pancreatectomy for malignancy, highlighting robotic surgery’s safety and specific perioperative advantages, notably reduced blood loss and conve
This study unravels how tumour-derived NGAL induces NETs that reprogram fibroblast subtypes via ITGA5, promoting immunosuppression and tumour progression in pancreatic ductal adenocarcinoma, suggesting combinatorial therapies to enhance imm
This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and
Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.
A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.
Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.
KRAS mutation and high glucose promote O-GlcNAcylation of CLDN18.2 in pancreatic cancer, pushing the protein off the cell membrane, boosting metastasis, and weakening CLDN18.2-targeted therapy. Low-dose MRTX1133 may restore sensitivity.
A UK Biobank study found that lifestyle-related pancreatic cancer risks were strongest in younger adults, especially those with high genetic risk, supporting early prevention efforts.
Single-cell analysis reveals CD276/B7-H3 as a critical regulator of chemoresistance in pancreatic ductal adenocarcinoma, highlighting its dual role in promoting basal-like tumor states and immune evasion.
Researchers developed PRIME, a parsimonious risk stratification model for pancreatic ductal adenocarcinoma using electronic health record data. Validated across US health systems and the UK Biobank, PRIME retained 19 predictors and achieved
